Latest update on the use of recombinant growth factors for periodontal regeneration: existing evidence and clinical applications

Growth factors were introduced to increase predictability in periodontal regeneration and have since been widely applied in dentistry. This narrative review article highlights histological and latest findings of recombinant human platelet-derived growth factor-BB (rhPDGF-BB) and recombinant human fi...

Full description

Saved in:
Bibliographic Details
Main Authors: Anahat Khehra, Takahiko Shiba, Chia-Yu Chen, David M. Kim
Format: Article
Language:English
Published: SAGE Publishing 2024-11-01
Series:Therapeutic Advances in Chronic Disease
Online Access:https://doi.org/10.1177/20406223241302707
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850269886593368064
author Anahat Khehra
Takahiko Shiba
Chia-Yu Chen
David M. Kim
author_facet Anahat Khehra
Takahiko Shiba
Chia-Yu Chen
David M. Kim
author_sort Anahat Khehra
collection DOAJ
description Growth factors were introduced to increase predictability in periodontal regeneration and have since been widely applied in dentistry. This narrative review article highlights histological and latest findings of recombinant human platelet-derived growth factor-BB (rhPDGF-BB) and recombinant human fibroblast growth factor-2 (rhFGF-2) for periodontal regeneration. rhPDGF-BB enhances the proliferation and chemotaxis of periodontal ligament and alveolar bone cells. The optimal dose for rhPDGF-BB, in combination with beta-tricalcium phosphate, is 0.3 mg/ml. It is approved in the United States, Canada, and Taiwan for use in periodontal regeneration and treatment of gingival recession. rhFGF-2 promotes periodontal wound healing through mitogenic and angiogenic effects on mesenchymal cells in the periodontal ligament. It is approved in Japan at an optimal dose of 0.3% for periodontal regeneration in intrabony defects. Both recombinant growth factors show histological evidence of new bone, cementum, and periodontal ligament. Clinical studies demonstrate improved clinical attachment levels and defect resolution for treating intrabony and furcation periodontal defects. Presented clinical cases and consensus reports may serve as a reference for clinicians. rhPDGF-BB and rhFGF-2 are safe and effective biologics that can be applied to improve the outcomes of periodontal regeneration.
format Article
id doaj-art-8388b3c7ab2e4592938e82df9396f66a
institution OA Journals
issn 2040-6231
language English
publishDate 2024-11-01
publisher SAGE Publishing
record_format Article
series Therapeutic Advances in Chronic Disease
spelling doaj-art-8388b3c7ab2e4592938e82df9396f66a2025-08-20T01:52:54ZengSAGE PublishingTherapeutic Advances in Chronic Disease2040-62312024-11-011510.1177/20406223241302707Latest update on the use of recombinant growth factors for periodontal regeneration: existing evidence and clinical applicationsAnahat KhehraTakahiko ShibaChia-Yu ChenDavid M. KimGrowth factors were introduced to increase predictability in periodontal regeneration and have since been widely applied in dentistry. This narrative review article highlights histological and latest findings of recombinant human platelet-derived growth factor-BB (rhPDGF-BB) and recombinant human fibroblast growth factor-2 (rhFGF-2) for periodontal regeneration. rhPDGF-BB enhances the proliferation and chemotaxis of periodontal ligament and alveolar bone cells. The optimal dose for rhPDGF-BB, in combination with beta-tricalcium phosphate, is 0.3 mg/ml. It is approved in the United States, Canada, and Taiwan for use in periodontal regeneration and treatment of gingival recession. rhFGF-2 promotes periodontal wound healing through mitogenic and angiogenic effects on mesenchymal cells in the periodontal ligament. It is approved in Japan at an optimal dose of 0.3% for periodontal regeneration in intrabony defects. Both recombinant growth factors show histological evidence of new bone, cementum, and periodontal ligament. Clinical studies demonstrate improved clinical attachment levels and defect resolution for treating intrabony and furcation periodontal defects. Presented clinical cases and consensus reports may serve as a reference for clinicians. rhPDGF-BB and rhFGF-2 are safe and effective biologics that can be applied to improve the outcomes of periodontal regeneration.https://doi.org/10.1177/20406223241302707
spellingShingle Anahat Khehra
Takahiko Shiba
Chia-Yu Chen
David M. Kim
Latest update on the use of recombinant growth factors for periodontal regeneration: existing evidence and clinical applications
Therapeutic Advances in Chronic Disease
title Latest update on the use of recombinant growth factors for periodontal regeneration: existing evidence and clinical applications
title_full Latest update on the use of recombinant growth factors for periodontal regeneration: existing evidence and clinical applications
title_fullStr Latest update on the use of recombinant growth factors for periodontal regeneration: existing evidence and clinical applications
title_full_unstemmed Latest update on the use of recombinant growth factors for periodontal regeneration: existing evidence and clinical applications
title_short Latest update on the use of recombinant growth factors for periodontal regeneration: existing evidence and clinical applications
title_sort latest update on the use of recombinant growth factors for periodontal regeneration existing evidence and clinical applications
url https://doi.org/10.1177/20406223241302707
work_keys_str_mv AT anahatkhehra latestupdateontheuseofrecombinantgrowthfactorsforperiodontalregenerationexistingevidenceandclinicalapplications
AT takahikoshiba latestupdateontheuseofrecombinantgrowthfactorsforperiodontalregenerationexistingevidenceandclinicalapplications
AT chiayuchen latestupdateontheuseofrecombinantgrowthfactorsforperiodontalregenerationexistingevidenceandclinicalapplications
AT davidmkim latestupdateontheuseofrecombinantgrowthfactorsforperiodontalregenerationexistingevidenceandclinicalapplications